可溶性HER3可预测膀胱癌患者的生存率。
Soluble HER3 predicts survival in bladder cancer patients.
作者信息
Memon Ashfaque A, Gilliver Stephen C, Borre Michael, Sundquist Jan, Sundquist Kristina, Nexo Ebba, Sorensen Boe S
机构信息
Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus DK-8200, Denmark.
Center for Primary Health Care Research, Lund University, 205 02 Malmö, Sweden.
出版信息
Oncol Lett. 2018 Feb;15(2):1783-1788. doi: 10.3892/ol.2017.7470. Epub 2017 Nov 22.
The role of soluble human epidermal growth factor receptor (sHER3) in bladder cancer remains unclear. In the present study, an ELISA was developed for the quantification of sHER3 and its role was investigated in patients with bladder cancer (n=82) followed for 10 years. Furthermore, the effects of sHER3 on bladder cancer cell growth and migration were also investigated. The results demonstrated that plasma sHER3 levels were significantly higher in non-invasive tumours (Ta) compared with muscle-invasive tumours (T2-T4). Higher sHER3 levels were associated with a more improved survival rate. However multivariate Cox regression analysis, adjusted for clinical stage, grade, type and size of the tumour, demonstrated that sHER3 was not an independent biomarker of survival. Exogenous sHER3 significantly inhibited bladder cancer cell growth and migration. These results suggest that high sHER3 levels are associated with improved survival rates in patients with bladder cancer, and that sHER3 inhibits bladder cancer cell growth and migration.
可溶性人表皮生长因子受体（sHER3）在膀胱癌中的作用仍不清楚。在本研究中，开发了一种用于定量sHER3的酶联免疫吸附测定（ELISA），并在随访10年的82例膀胱癌患者中研究了其作用。此外，还研究了sHER3对膀胱癌细胞生长和迁移的影响。结果表明，与肌层浸润性肿瘤（T2-T4）相比，非浸润性肿瘤（Ta）患者的血浆sHER3水平显著更高。较高的sHER3水平与更高的生存率相关。然而，在对肿瘤的临床分期、分级、类型和大小进行校正的多变量Cox回归分析中，sHER3并不是生存的独立生物标志物。外源性sHER3显著抑制膀胱癌细胞的生长和迁移。这些结果表明，高sHER3水平与膀胱癌患者生存率的提高相关，且sHER3可抑制膀胱癌细胞的生长和迁移。
Zotero 插件